Ovarian Smooth Muscle Neoplasm

A benign, intermediate, or malignant neoplasm that arises from the ovary and is composed of neoplastic cells with smooth muscle differentiation.


Ovarian Low Grade Endometrioid Stromal Sarcoma

biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:NamedThing biolink:Entity biolink:ThingWithTaxon

A rare invasive mesenchymal tumor that arises from the ovary.  It is characterized by the absence of marked pleomorphism and nuclear atypia in the neoplastic mesenchymal cells.  It may have a favorable clinical outcome.


Ovarian Sertoli Cell Tumor with Lipid Storage

A Sertoli cell tumor that arises from the ovary and is characterized by the presence of cells that are distended by the presence of intracytoplasmic lipid.


pediatric ovarian germ cell tumor

A germ cell tumor that arises from the ovary and occurs in children.


Ovarian Mesonephric-Like Adenocarcinoma

An exceedingly rare adenocarcinoma that arises from the ovary and displays mesonephric differentiation. Some tumors are thought to derive from mesonephric duct (Wolffian duct) remnants. Others may have a Mullerian duct lineage.


Recurrent Malignant Ovarian Granulosa Cell Tumor

The reemergence of malignant ovarian granulosa cell tumor after a period of remission.


Refractory Ovarian Transitional Cell Carcinoma

Ovarian transitional cell carcinoma that is resistant to treatment.


Stage I Ovarian Cancer AJCC v6 and v7

Stage I includes: T1, N0, M0. T1: Tumor limited to ovaries (one or both).  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)


Benign Ovarian Seromucinous Tumor

A non-metastasizing mixed epithelial neoplasm that arises from the ovary. It is characterized by the presence of more than one epithelial cell type, most often serous and endocervical-type mucinous. This category includes seromucinous cystadenoma and seromucinous adenofibroma.


Ovarian Carcinoid Tumor

A well differentiated neuroendocrine neoplasm that arises from the ovary.  Histologically, it is classified as insular, trabecular, mucinous, or stromal carcinoid.  Clinical manifestations of carcinoid syndrome occur in approximately thirty percent of patients with insular carcinoid tumor.  Carcinoid syndrome is rare in other types of primary ovarian carcinoid tumor.  With the exception of mucinous carcinoid tumor, the prognosis is favorable.  Primary ovarian mucinous carcinoid tumor has a more aggressive clinical course and it can metastasize to other anatomic sites.


Ovarian cancer stage III

Stage III includes: T3, N0, M0.  T3: Tumor involves one or both ovaries with microscopically confirmed peritoneal metastasis outside pelvis.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Borderline Ovarian Endometrioid Adenofibroma

An epithelial neoplasm that arises from the ovary characterized by the presence of glandular or cystic spaces which contain atypical glandular epithelial cells resembling endometrial cells. The surrounding ovarian stroma is fibrotic. There is no evidence of stromal invasion.


Stage IIA Ovarian Germ Cell Tumor AJCC v6 and v7

Stage IIA includes: T2a, N0, M0. T2a: Extension and/or implants on uterus and/or tube(s). No malignant cells in ascites or peritoneal washings. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


FIGO Stage IC1 Ovarian Cancer

Stage IC ovarian cancer with surgical spill. (FIGO, 2014)


ovarian primitive germ cell tumor

A malignant tumor that arises from the ovary and is characterized by the presence of malignant germ cell components but lacks a teratoma component.


Ovarian Cancer by FIGO Stage

A category of staging terms for ovarian cancer according to the International Federation of Gynecology and Obstetrics (FIGO), 2014. AJCC ovarian cancer stage terms from the 6th and 7th editions that are synonymous to the FIGO ovarian cancer staging classification of 2014 are included as preferred terms.


Metastatic Ovarian Endometrioid Adenocarcinoma

Ovarian endometrioid adenocarcinoma that has spread from its original site of growth to another anatomic site.


Platinum-Refractory Ovarian Carcinoma

Ovarian carcinoma that progresses during platinum therapy or within one month of completing the last platinum therapy.


liposarcoma of the ovary

A malignant adipose tissue neoplasm of the ovary.


Borderline Ovarian Seromucinous Tumor/Atypical Proliferative Ovarian Seromucinous Tumor with Microinvasion

A low grade ovarian epithelial neoplasm characterized by the presence of atypical neoplastic serous and mucinous cells. Microinvasion of the ovarian stroma is present.


Benign germ cell tumor of ovary

A non-metastasizing germ cell tumor that arises from the ovary.  The vast majority of cases are benign dermoid cysts.


Ovarian Sertoli Cell Tumor

A rare, typically benign ovarian neoplasm composed of Sertoli cells. Patients may present with pseudoprecocity, menometrorrhagia, amenorrhea, hirsutism, and hoarseness.  Rarely it may invade the ovarian stroma and extend beyond the ovary.


FIGO Stage IIIC Ovarian Cancer

Ovarian cancer with macroscopic, extrapelvic, peritoneal metastasis greater than 2 cm +/- positive retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen. (FIGO, 2014)


childhood choriocarcinoma of the ovary

A non-gestational choriocarcinoma that arises from the ovary and occurs in children.


Metastatic Ovarian Small Cell Carcinoma, Hypercalcemic Type

A primary small cell carcinoma of the ovary that is associated with hypercalcemia and has metastasized to other anatomic sites.


Borderline Ovarian Endometrioid Tumor/Atypical Proliferative Ovarian Endometrioid Tumor

An epithelial neoplasm that arises from the ovary characterized by the presence of glandular or cystic spaces which contain atypical glandular epithelial cells resembling endometrial cells. The surrounding ovarian stroma is often fibrotic. There is no evidence of stromal invasion.


Borderline Ovarian Serous Tumor/Atypical Proliferative Ovarian Serous Tumor with Microinvasion

A low grade ovarian epithelial neoplasm characterized by the presence of neoplastic serous epithelial cells, atypia, and microinvasion of the ovarian stroma.


Ovarian Cellular Fibroma

A benign neoplasm arising from soft tissue of the ovary. It is characterized by the presence of spindle-shaped fibroblasts and increased cellularity.


Borderline Ovarian Seromucinous Tumor/Atypical Proliferative Ovarian Seromucinous Tumor

A low grade, non-invasive ovarian epithelial neoplasm characterized by the presence of atypical neoplastic serous and mucinous cells.


Benign Ovarian Serous Tumor

A non-metastasizing neoplasm that arises from the ovary and is characterized by the presence of neoplastic epithelium that resembles the epithelium of the fallopian tube.  It includes serous cystadenoma, serous adenofibroma, serous cystadenofibroma, and surface papilloma.


Moderately Differentiated Ovarian Sertoli-Leydig Cell Tumor

A Sertoli-Leydig cell tumor of the ovary characterized by the presence of spindle-shaped gonadal stromal cells and Sertoli cells, some of which are atypical. Leydig cells are also present forming clusters at the periphery of the cellular aggregates. Metastases have been reported in a minority of patients.


Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor

The reemergence of borderline ovarian epithelial tumor after a period of remission.


Ovarian Adenomatoid Tumor

A rare benign mesothelial tumor that arises from the ovary. It is characterized by the presence of gland-like structures.


Ovarian Sex Cord-Stromal Tumor Associated with Peutz-Jeghers Syndrome

A sex cord-stromal tumor that arises from the ovary in a patient diagnosed with Peutz-Jeghers syndrome.


Stage III Ovarian Polyembryoma AJCC v6 and v7

Stage III includes: T3, N0, M0. T3: Tumor involves one or both both ovaries with microscopically confirmed peritoneal metastasis outside pelvis. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Juvenile Bilateral Ovarian Granulosa Cell Tumor

A granulosa cell tumor that involves both ovaries. It affects females in the first three decades of life.


Refractory Ovarian Adenocarcinoma

Ovarian adenocarcinoma that is resistant to treatment.


Stage III Ovarian Dysgerminoma AJCC v6 and v7


Ovarian Fibromatosis and Massive Edema

A rare benign lesion characterized by tumor-like enlargement of the ovaries due to fibroblastic proliferation with collagen deposition (fibromatosis) or stromal accumulation of edema fluid (massive edema). It presents in premenopausal patients, with menstrual abnormalities, abdominal pain, or androgenic manifestations. Most cases are unilateral. (WHO 2020)


luteoma of pregnancy

A non-neoplastic and self-limited condition that occurs during pregnancy. It is characterized by proliferation of luteinized stromal cells that replace the normal ovarian stromal cells. It is usually manifested with bilateral multinodular ovarian masses. Treatment is not required.


Ovarian Sertoli-Leydig Cell Tumor with Heterologous Elements

A Sertoli-Leydig cell tumor that arises from the ovary. It is characterized by the presence of epithelial and/or mesenchymal components and neoplasms that arise from these components.


Microsatellite Stable Ovarian Carcinoma

Ovarian carcinoma characterized by the absence of microsatellite instability.


Ovarian Trabecular Carcinoid Tumor

A carcinoid tumor that arises from the ovary and is characterized by the presence of columnar cells with abundant cytoplasm forming ribbons.  The prognosis is excellent.


Mucinous adenofibroma of borderline malignancy

A low malignant potential adenofibroma of the ovary It is characterized by an atypical epithelial hyperplasia. The epithelial cells contain intracytoplasmic mucin. There is no evidence of stromal destructive invasion.


Stage IC Ovarian Cancer AJCC v6 and v7

Stage IC includes: T1c, N0, M0. T1c: Tumor limited to one or both ovaries with any of the following: capsule ruptured, tumor on ovarian surface, malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Refractory Malignant Ovarian Brenner Tumor

Malignant ovarian Brenner tumor that is resistant to treatment.


Stage IIB Ovarian Cancer AJCC v6 and v7

Stage IIB includes: T2b N0, M0.  T2b: Extension and/or implants on other pelvic tissues.  No malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


ovarian granulosa cell tumor

A granulosa-stromal cell tumor that arises from the ovary. It is characterized by the presence of granulosa cells that comprise at least ten percent of the cellular population. The granulosa cells are often found in a background that contains theca and fibrous cells. There are two major subtypes recognized, adult and juvenile granulosa cell tumor. Clinically, patients may present with an abdominal mass. Symptoms depend on the patient's age. The most important indicator of prognosis is tumor stage. Age over forty years at the time of the initial diagnosis, large tumor size, bilaterality, cellular atypia, and increased mitotic activity are factors indicating a potentially aggressive clinical course and relative poor prognosis.


Clear cell adenofibroma of borderline malignancy

An epithelial neoplasm with low malignant potential affecting the ovary. It is characterized by the presence of atypical glands and/or cystic spaces lined with clear or hobnail cells.


Stage IB Ovarian Cancer AJCC v6 and v7

Stage IB includes: T1b, N0, M0. T1b: Tumor limited to both ovaries; capsules intact, no tumor on ovarian surface.  No malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Borderline Ovarian Serous Cystadenofibroma

A neoplasm of low malignant potential arising from the ovary. It is characterized by the presence of cystic spaces which are lined by atypical serous epithelial cells. The surrounding ovarian stroma is fibrotic. There is no evidence of stromal invasion.


Hilus cell tumor

A benign Leydig cell tumor which arises in the hilar area of the ovary.


Benign Brenner Tumor

A benign neoplasm that arises from the ovary and is composed of nests of transitional cells in a fibrotic stroma. There is no evidence of invasion.


Platinum-Sensitive Ovarian Carcinoma

Ovarian carcinoma that has a documented response to platinum-based chemotherapy.


Unresectable Ovarian Carcinoma

Ovarian carcinoma that is not amenable to surgical resection.


Borderline Ovarian Clear Cell Cystadenofibroma

An epithelial neoplasm with low malignant potential affecting the ovary. It is characterized by the presence of prominent cystic spaces lined with atypical clear or hobnail cells. There is no evidence of stromal invasion.


ovarian Wilms tumor

An embryonal neoplasm arising from the ovary with morphologic features resembling Wilms tumor of the kidney. It occurs during the reproductive age and may present as a rapidly growing adnexal mass.


Recurrent Ovarian Cystadenocarcinoma

The reemergence of ovarian cystadenocarcinoma after a period of remission.


Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7

Stage II includes: T2, N0, M0. T2: Tumor involves one or both ovaries with pelvic extension and/or implants. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Borderline Ovarian Serous Adenofibroma

A low malignant potential adenofibroma arising from the ovary. It is characterized by an atypical epithelial hyperplasia. The epithelial cells are of serous type. There is no evidence of stromal destructive invasion.


Stage IA Ovarian Cancer AJCC v8

Stage IA includes: T1a, N0, M0. T1a: Ovarian cancer with tumor limited to one ovary (capsule intact); no malignant cells in ascites or peritoneal washings. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)


Childhood Malignant Ovarian Germ Cell Tumor

A malignant germ cell tumor in children arising from the ovary.  It includes the dysgerminoma, yolk sac tumor, choriocarcinoma, embryonal carcinoma and immature teratoma.


Borderline Ovarian Clear Cell Tumor

An epithelial neoplasm with low malignant potential affecting the ovary.  It is characterized by the presence of clear or hobnail cells.  In some cases, the cells may display nuclear atypia and prominent nucleoli.  When such cells are present, they remain confined to the glands.  There is no evidence of stromal invasion.


Congenital Ovarian Failure

Ovarian failure, the cause of which is present at birth.


Stage I Ovarian Cancer AJCC v8

Stage I includes: T1, N0, M0. T1: Ovarian cancer with tumor limited to ovaries (one or both). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)


Stage IIIA Ovarian Cancer AJCC v8

Stage IIIA includes: IIIA1: T1/2, N1, M0; IIIA2: T3a, N0/N1, M0. T1: Ovarian cancer with tumor limited to ovaries (one or both). T2: Ovarian cancer with tumor involving one or both ovaries with pelvic extension below pelvic brim. T3a: Ovarian cancer with microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)


Ovarian Stromal Tumor with Minor Sex Cord Elements

A rare, benign sex cord-stromal tumor of the ovary characterized by the presence of a fibrothecomatous stroma and scattered sex cord elements. Although it is usually hormonally inactive, cases associated with endometrial hyperplasia or adenocarcinoma have been reported.


Sertoli-Leydig cell tumor, retiform

A Sertoli-Leydig cell tumor characterized by the presence of spaces that resemble rete testis (retiform elements).  These spaces form anastomosing patterns and comprise at least ten percent but less than ninety percent of the tumor.  When the retiform elements comprise ninety percent or more of the tumor, the term retiform Sertoli-Leydig cell tumor is used.  A minority of patients may have an aggressive clinical course.


Childhood Ovarian Nongerminomatous Germ Cell Tumor

A nongerminomatous germ cell tumor that arises in the ovary and occurs in children.


Ovarian Mixed Germ Cell-Sex Cord-Stromal Tumor

A neoplasm that arises from the ovary and is characterized by the presence of germ cell and sex cord-stromal tissues that are intimately admixed.  If there is no malignant germ cell component present, the clinical course is benign.


Malignant Ovarian Steroid Cell Tumor

A steroid tumor of the ovary which has an aggressive clinical course and metastasizes to other anatomic sites. It is usually of large size and is characterized by nuclear atypia, increased mitotic activity, hemorrhage, and necrosis. Sometimes, patients have abdominal metastases at presentation.


Ovarian Insular Carcinoid Tumor

A carcinoid tumor that arises from the ovary and is characterized by the presence of round cells with abundant eosinophilic cytoplasm forming cribriform patterns.  Clinical manifestations of carcinoid syndrome occur in approximately thirty percent of patients.  The prognosis is favorable.


Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor

Stage IV includes: Any T, Any N, M1.  M1: Distant metastasis (excludes peritoneal metastasis). (AJCC 6th and 7th eds.)


Ovarian Mixed Germ Cell-Sex Cord-Stromal Tumor, Unclassified

An ovarian mixed germ cell-sex cord-stromal tumor in which the neoplastic cellular infiltrate does not have the distinctive appearance of a gonadoblastoma.


Unresectable Ovarian Endometrioid Adenocarcinoma

Ovarian endometrioid adenocarcinoma that is not amenable to surgical resection.


Recurrent ovarian cancer

The reemergence of ovarian carcinoma after a period of remission.


ovarian neuroendocrine neoplasm

An epithelial neoplasm with neuroendocrine differentiation that arises from the ovary. It includes carcinoid tumor, small cell carcinoma pulmonary type, and large cell neuroendocrine carcinoma.


Ovarian Leiomyoma

A benign smooth muscle neoplasm arising from the ovary. It is usually characterized by the presence of spindle cells with cigar-shaped nuclei, interlacing fascicles, and a whorled pattern. Variants with increased cellularity, increased mitotic activity, myxoid changes, or epithelioid morphology have also been reported.


ovarian benign neoplasm

A non-metastasizing neoplasm that arises from the ovary. Representative examples include serous cystadenoma, mucinous cystadenoma, clear cell adenofibroma, benign Brenner tumor, thecoma, and fibroma.


Refractory Ovarian Mucinous Adenocarcinoma

Ovarian mucinous adenocarcinoma that is resistant to treatment.


Ovarian Torsion

Twisting of the ovary resulting in the cutoff of the blood supply to the ovary. It may develop in an enlarged or normal ovary and in the vast majority of cases is unilateral. Signs and symptoms include acute lower abdominal pain, nausea, vomiting, and fever.


Ovarian Signet Ring Cell Carcinoma

An extremely rare adenocarcinoma that arises from the ovary. It is characterized by the presence of signet ring malignant epithelial cells.


Ovarian Leydig Cell Tumor

An ovarian Leydig cell tumor for which the site of origin (ovarian hilus or ovarian stroma) cannot be determined.


Recurrent Ovarian Seromucinous Carcinoma

The reemergence of ovarian seromucinous carcinoma after a period of remission.


Stage IIC Ovarian Carcinoma

Stage IIC includes: T2c, N0, M0.  T2c: Pelvic extension and/or implants (T2a or T2b) with malignant cells in ascites or peritoneal washing.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Recurrent Platinum-Resistant Ovarian Carcinoma

The reemergence of platinum-resistant ovarian carcinoma after a period of remission.


Recurrent Ovarian Germ Cell Tumor

The reemergence of ovarian germ cell tumor after a period of remission.


Stage IA Ovarian Cancer

Stage IA includes: T1a, N0, M0.  T1a: Tumor limited to one ovary; capsule intact, no tumor on ovarian surface.  No malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Borderline Ovarian Endometrioid Tumor/Atypical Proliferative Ovarian Endometrioid Tumor with Microinvasion

A low grade ovarian epithelial neoplasm characterized by the presence of glandular or cystic spaces which contain atypical glandular epithelial cells resembling endometrial cells. Microinvasion of the ovarian stroma is present.


Ovarian Cancer by AJCC v6 and v7 Stage

A category of staging terms for ovarian cancer according to the American Joint Committee on cancer (AJCC) 6th and 7th editions. International Federation of Gynecology and Obstetrics (FIGO) ovarian cancer staging terms prior to 2014 are included in this category if synonymous with the AJCC terms.


Stage II Ovarian Dysgerminoma AJCC v6 and v7

Stage II includes: T2, N0, M0. T2: Tumor involves one or both ovaries with pelvic extension and/or implants. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Refractory Ovarian Undifferentiated Carcinoma

Ovarian undifferentiated carcinoma that is resistant to treatment.


Metastatic Ovarian Undifferentiated Carcinoma

Ovarian undifferentiated carcinoma that has spread from its original site of growth to another anatomic site.


Recurrent Ovarian Endometrioid Adenocarcinoma

The reemergence of ovarian endometrioid adenocarcinoma after a period of remission.


Stage IV Ovarian Germ Cell Tumor AJCC v6 and v7

Stage IV includes: Any T, Any N, M1. M1: Distant metastasis (excludes peritoneal metastasis). (AJCC 6th and 7th eds.)


ovarian germ cell tumor

A neoplasm that arises from the ovary and originates from germ cells. Representative examples include teratoma, embryonal carcinoma, yolk sac tumor, and dysgerminoma.


Ovarian stromal hyperplasia

A non-neoplastic disorder that usually affects postmenopausal women.  It is characterized by proliferation of ovarian stromal cells without evidence of atypia.  There is usually bilateral ovarian involvement.  The ovaries may or may not be enlarged.


FIGO Stage IC2 Ovarian Cancer

Stage IC ovarian cancer with capsule rupture before surgery or tumor on ovarian surface. (FIGO, 2014)


ovary leiomyosarcoma

An aggressive malignant smooth muscle neoplasm, arising from the ovary. It is characterized by a proliferation of neoplastic spindle cells.


Lipid cell tumor of ovary

An ovarian tumor in which the vast majority of the cells (more than 90% of the tumor cells) resemble steroid hormone-secreting cells. It usually presents with androgenic manifestations. Approximately one-third of the cases follow a malignant clinical course.


Metastatic Microsatellite Stable Ovarian Carcinoma

Microsatellite stable ovarian carcinoma that has spread from its original site of growth to another anatomic site.


Borderline Ovarian Endometrioid Tumor

A rare, low grade ovarian epithelial neoplasm characterized by the presence of glandular or cystic spaces which contain atypical glandular epithelial cells resembling endometrial cells.


FIGO Stage IC3 Ovarian Cancer

Stage IC ovarian cancer with malignant cells in the ascites or peritoneal washings. (FIGO, 2014)


Stage IV Ovarian Dysgerminoma AJCC v6 and v7


Stage IC Ovarian Cancer AJCC v8

Stage IC includes: T1c, N0, M0. T1c: Ovarian cancer with tumor limited to one or both ovaries, with any of the following: surgical spill, capsule ruptured before surgery or tumor on ovarian surface, or malignant cells in ascites or peritoneal washings. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)


Ovarian Sclerosing Stromal Tumor

A benign ovarian stromal tumor characterized by the presence of cellular areas which contain fibroblasts and round cells. The cellular areas are separated by sclerotic or edematous hypocellular tissue. Symptoms include abdominal discomfort and menstrual abnormalities.


Stage IA Ovarian Germ Cell Tumor AJCC v6 and v7

Stage IA includes: (T1a, N0, M0). T1a: Tumor limited to one ovary; capsule intact, no tumor on ovarian surface.  No malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th Eds.)


Metastatic Platinum-Resistant Ovarian Carcinoma

Platinum-resistant ovarian carcinoma that has spread from its original site of growth to another anatomic site.


FIGO Stage IVB Ovarian Cancer

Ovarian cancer with hepatic and/or splenic parenchymal metastasis, metastasis to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside of the abdominal cavity). (FIGO, 2014)


Benign Ovarian Clear Cell Tumor

A non-metastasizing neoplasm that arises from the ovary.  It is characterized by a predominance of clear and hobnail benign epithelial cells.


Recurrent Ovarian Clear Cell Adenocarcinoma

The reemergence of ovarian clear cell adenocarcinoma after a period of remission.


Metastatic Ovarian Mucinous Adenocarcinoma

Ovarian mucinous adenocarcinoma that has spread from its original site of growth to another anatomic site.


Ovarian Steroid Cell Tumor, Not Otherwise Specified

A steroid cell tumor that arises from the ovary and is defined by morphologic features that do not fit into the categories of Leydig cell tumor and stromal luteoma.  These features include solid proliferations of polygonal neoplastic cells with eosinophilic and granular cytoplasm.  Grossly, these tumors usually present as large and well circumscribed masses and are usually associated with androgenic manifestations.  Approximately one third of the cases have a malignant clinical course.


Stage IB Ovarian Cancer AJCC v8

Stage IB includes: T1b, N0, M0. T1b: Ovarian cancer with tumor limited to one or both ovaries (capsules intact); no tumor on ovarian surface; no malignant cells in ascites or peritoneal washings. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)


Refractory Ovarian Carcinoma

Ovarian carcinoma that is resistant to treatment.


Stage I Ovarian Polyembryoma AJCC v6 and v7

Stage I includes: (T1, N0, M0). T1: Tumor limited to ovaries (one or both).  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th Eds.)


Ovarian Granulosa-Stromal Cell Tumor

A group of sex cord-stromal tumors that arise from the ovary.  These tumors are characterized by the presence of granulosa cells, stromal cells, and/or theca cells.  This group includes granulosa cell tumor and tumors of the thecoma/fibroma group.


ovarian melanoma

A melanoma (disease) that involves the ovary.


Refractory Ovarian Endometrioid Adenocarcinoma

Ovarian endometrioid adenocarcinoma that is resistant to treatment.


Ovarian Neuroectodermal-Type Tumor

A rare ovarian malignant tumor with neuroectodermal differentiation. It is characterized either by a small round cell proliferation or by neuronal or glial differentiation.


Sertoli-Leydig cell tumor, intermediate differentiation, with heterologous elements

An ovarian Sertoli-Leydig cell tumor of intermediate differentiation, characterized by the presence of a heterologous component, usually consisting of cartilage, skeletal muscle, or rhabdomyosarcoma.


Ovarian epithelial cancer stage II

Stage II includes: T2, N0, M0.  T2: Tumor involves one or both ovaries with pelvic extension and/or implants.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


malignant germ cell tumor of ovary

Malignant germ cell tumor of ovary is a rare ovarian cancer arising from germ cells in the ovary, frequently unilateral at diagnosis which characteristically presents during adolescence with pelvic mass, fever, vaginal bleeding and acute abdomen.


Borderline Ovarian Serous Tumor-Micropapillary Variant/Non-Invasive Low Grade Ovarian Serous Carcinoma

A non-invasive serous neoplasm that arises from the ovary and shows micropapillary and/or cribriform architectural patterns.  It is composed of round epithelial cells with scant cytoplasm and moderate nuclear atypia.


Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7

Stage IV includes: Any T, Any N, M1. M1: Distant metastasis (excludes peritoneal metastasis). (AJCC 6th and 7th eds.)


Poorly Differentiated Ovarian Sertoli-Leydig Cell Tumor, Variant with Heterologous Elements

An ovarian poorly differentiated Sertoli-Leydig cell tumor. It is characterized by the presence of a heterologous component, usually consisting of cartilage, skeletal muscle, or rhabdomyosarcoma.


Well Differentiated Ovarian Sertoli-Leydig Cell Tumor

A Sertoli-Leydig tumor of the ovary characterized by the presence of Sertoli cells in tubules without evidence of significant nuclear atypia or mitotic activity. Primitive gonadal stromal cells are not present. It usually follows a benign clinical course.


ovarian endometrioid adenofibroma

A benign neoplasm of the ovary characterized by the presence of glandular structures with endometrial-type well-differentiated cells in a fibrotic stroma.


Stage IIIA2 Ovarian Cancer AJCC v8

Stage IIIA2 includes: T3a, N0/N1, M0. T3a: Ovarian cancer with microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)


Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7


Ovarian Retiform Sertoli-Leydig Cell Tumor, Variant with Heterologous Elements

A retiform Sertoli-Leydig cell tumor that arises from the ovary. It is characterized by the presence of an epithelial and/or mesenchymal heterologous component.


undifferentiated sarcoma of ovary

An aggressive high grade sarcoma that arises from the ovary.  It is characterized by the presence of marked pleomorphism and nuclear atypia in the neoplastic mesenchymal cells.  The prognosis is poor.


Stage IIIA1 Ovarian Cancer AJCC v8

Stage IIIA1 includes: T1/2, N1, M0. T1: Ovarian cancer with tumor limited to ovaries (one or both). T2: Ovarian cancer with tumor involving one or both ovaries with pelvic extension below pelvic brim. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)


Stage IIC Ovarian Germ Cell Tumor AJCC v6 and v7

Stage IIC includes: T2c, N0, M0. T2c: Pelvic extension and/or implants (T2a or T2b) with malignant cells in ascites or peritoneal washing. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Ovarian Leydig Cell Tumor, Non-Hilar Type

A Leydig cell tumor that arises from the ovarian stroma.


Benign thecoma

A thecoma of the ovary that does not metastasize to other anatomic sites.


Borderline Ovarian Mucinous Tumor, Intestinal Type

A neoplasm of low malignant potential arising from the ovary.  It is characterized by the proliferation of neoplastic mucinous epithelial cells that resemble intestinal epithelial cells.  There is no evidence of stromal invasion.


ovarian sarcoma

A rare, aggressive malignant mesenchymal neoplasm that arises from the ovary. The prognosis is poor.


FIGO Stage III Ovarian Cancer

Ovarian cancer involving 1 or both ovaries with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes. (FIGO, 2014)


FIGO Stage II Ovarian Cancer

Ovarian cancer involving one or both ovaries with pelvic extension (below the pelvic brim) or primary peritoneal cancer. (FIGO, 2014)


Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7

Stage I includes: (T1, N0, M0). T1: Tumor limited to ovaries (one or both).  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th Eds.)


Advanced Ovarian Carcinosarcoma

Ovarian carcinosarcoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Recurrent Extrarenal Rhabdoid Tumor of the Ovary

The reemergence of extrarenal rhabdoid tumor of the ovary after a period of remission.


Extrarenal Rhabdoid Tumor of the Ovary

An extrarenal rhabdoid tumor affecting the ovary.


Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7

Stage III includes: T3, N0, M0. T3: Tumor involves one or both both ovaries with microscopically confirmed peritoneal metastasis outside pelvis. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


adenocarcinofibroma

A carcinoma arising from the ovary. It is characterized by the presence of malignant epithelial cells in a fibrotic stroma. Histologic variants include clear cell, serous, mucinous, and endometrioid adenocarcinofibroma.


Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor

Stage III includes: T3, N0, M0.  T3: Tumor involves one or both ovaries with microscopically confirmed peritoneal metastasis outside pelvis.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Adult Type Ovarian Granulosa Cell Tumor

A granulosa cell tumor that affects middle aged or postmenopausal women.  Patients may present with uterine bleeding.


Stage II Ovarian Germ Cell Tumor AJCC v6 and v7

Stage II includes: T2, N0, M0. T2: Tumor involves one or both ovaries with pelvic extension and/or implants. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Recurrent Ovarian Mucinous Adenocarcinoma

The reemergence of ovarian mucinous adenocarcinoma after a period of remission.


Acquired Ovarian Failure

Ovarian failure, the cause of which is not present at birth.


serous adenocarcinofibroma of ovary

A malignant neoplasm of the ovary with an invasive epithelial component and a fibrotic stroma. The epithelial component is characterized by the presence of malignant epithelial cells of serous type, forming glandular, papillary, and solid patterns.


Stage IV Ovarian Carcinoma

A carcinoma that arises from the ovary and has metastasized to another anatomic site.


Ovarian Non-Neoplastic Disorder

A non-neoplastic disorder that affects the ovary.  Representative examples include endometriosis and polycystic ovarian disease.


Borderline Ovarian Mucinous Tumor, Endocervical-Like

A neoplasm of low malignant potential arising from the ovary.  It is characterized by the proliferation of neoplastic epithelial cells that resemble endocervical epithelial cells.  There is no evidence of stromal invasion.


Gonadotropin-Resistant Ovary Syndrome

Ovarian dysfunction due to a defect at the receptor or post receptor level, or due to the presence of antibodies against gonadotropin receptors, resulting in deficient gonadotropin signaling that causes elevated concentrations of follicle stimulating hormone and/or luteinizing hormone. A distinguishing feature is the presence of normal numbers of ova.


Borderline Ovarian Seromucinous Tumor

A low grade ovarian epithelial neoplasm characterized by the presence of atypical neoplastic serous and mucinous cells.


BRCA-Associated Ovarian Carcinoma

Ovarian carcinoma caused by deleterious germline mutation in a gene of the BRCA family.


Solid Pseudopapillary Neoplasm of the Ovary

An exceedingly rare solid pseudopapillary tumor that occurs in ectopic pancreatic tissue in the ovary.


Thecoma, luteinized

A variant of ovarian thecoma characterized by the presence of lutein cells. It is associated with a lower frequency of estrogenic manifestations compared to typical thecomas. In a minority of cases androgenic manifestations are present.


Ovarian Tumor of the Thecoma/Fibroma Group

A group of neoplasms that arise from the ovary and represent a spectrum of tumors ranging from neoplasms that are composed entirely of fibroblasts to those that are composed predominantly of theca cells.


Ovarian Luteinized Thecoma Associated with Sclerosing Peritonitis

A rare usually bilateral luteinized thecoma that arises from the ovary and is associated with sclerosing peritonitis. It occurs mostly in premenopausal women. The ovarian tumor is benign but patients may develop intestinal obstruction due to the sclerosing peritonitis.


Ovarian germ cell choriocarcinoma stage III

Stage III includes: T3, N0, M0. T3: Tumor involves one or both both ovaries with microscopically confirmed peritoneal metastasis outside pelvis. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IIA Ovarian Cancer AJCC v8

Stage IIA includes: T2a, N0, M0. T2a: Ovarian cancer with tumor extension and/or implants on the uterus and/or fallopian tube(s) and/or ovaries. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)


Unresectable Ovarian Undifferentiated Carcinoma

Ovarian undifferentiated carcinoma that is not amenable to surgical resection.


FIGO Stage IIIA1 Ovarian Cancer

Ovarian cancer with positive retroperitoneal lymph nodes only. (FIGO, 2014)


Platinum-Resistant Ovarian Carcinoma

Ovarian carcinoma that progresses between one and six months of completing the last platinum therapy.


Stage IIIA Ovarian Carcinoma

Ovarian cancer with positive retroperitoneal lymph nodes and/or microscopic metastasis beyond the pelvis. (FIGO, 2014)


Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7


FIGO Stage IIIA1(ii) Ovarian Cancer

Ovarian cancer with positive retroperitoneal lymph nodes only. Metastasis greater than 10 mm. (FIGO, 2014)


Refractory Ovarian Seromucinous Carcinoma

Ovarian seromucinous carcinoma that is resistant to treatment.


ovarian sertoli-stromal cell tumor

A sex cord-stromal tumor that arises from the ovary and is composed entirely of, or in various combinations of, Sertoli cells, Leydig cells, and fibroblast-like cells.


Stage II Ovarian Cancer AJCC v8

Stage II includes: T2, N0, M0. T2: Ovarian cancer with tumor involving one or both ovaries with pelvic extension below pelvic brim. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)


Benign Ovarian Luteinized Thecoma

A non-metastasizing thecoma of the ovary that is characterized by the presence of lutein cells.


ovarian malignant mesothelioma

A rare malignant mesothelial neoplasm that usually involves both the ovarian surface and the ovarian stroma. In most cases there is bilateral ovarian involvement.


Ovarian Seromucinous Adenofibroma

A non-metastasizing mixed epithelial neoplasm that arises from the ovary. It is characterized by the presence of more than one epithelial cell type, most often serous and endocervical-type mucinous and prominent fibrous stroma..


benign endometrioid tumor of ovary

A non-metastasizing neoplasm that arises from the ovary characterized by the presence of glands or cysts lined by benign endometrial-type cells.  It includes endometrioid adenofibroma, endometrioid cystadenofibroma, and endometrioid cystadenoma.


Stage IIIC Ovarian Germ Cell Tumor AJCC v6 and v7

Stage IIIC includes: (T3c, N0, M0); (Any T, N1, M0). T3c: Peritoneal metastasis beyond pelvis more than 2cm in greatest dimension and/or regional lymph node metastasis. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Proliferating Brenner Tumor

A transitional cell neoplasm of low malignant potential arising from the ovary.  It is characterized by the presence of neoplastic transitional cells with atypical features without evidence of stromal invasion.


Typical Ovarian Thecoma

An ovarian thecoma characterized by the presence of cells with uniform nuclei and abundant vacuolated cytoplasm.  Mitoses are not present or, when present, are rare.


Borderline Ovarian Mucinous Tumor/Atypical Proliferative Ovarian Mucinous Tumor with Intraepithelial Carcinoma

A low grade ovarian epithelial neoplasm characterized by the presence of neoplastic mucinous epithelial cells, atypia, and the presence of intraepithelial carcinoma.


Unresectable Ovarian Mucinous Adenocarcinoma

Ovarian mucinous adenocarcinoma that is not amenable to surgical resection.


choriocarcinoma of ovary

A choriocarcinoma arising from the ovary. When it appears before puberty is of germ cell origin. In children and young adults signs and symptoms include precocious pseudopuberty and vaginal bleeding. Serum human chorionic gonadotropin is elevated. Germ cell derived ovarian choriocarcinoma should be differentiated from primary or metastatic gestational choriocarcinoma affecting the ovary. The prognosis of germ cell derived choriocarcinoma is less favorable and requires more aggressive chemotherapy treatment regimens compared to gestational choriocarcinoma.


Ovarian Dedifferentiated Carcinoma

An aggressive carcinoma arising from the ovary.  Most patients present with advanced disease.  Microscopically, it is characterized by the presence of an undifferentiated carcinomatous component and a second component of either endometrioid carcinoma or, rarely, serous carcinoma.


Borderline Ovarian Endometrioid Cystadenofibroma

An epithelial neoplasm that arises from the ovary characterized by the presence of cystic spaces which are lined by atypical glandular epithelial cells resembling endometrial cells. The surrounding ovarian stroma is fibrotic. There is no evidence of stromal invasion.


Ovarian Sex Cord Tumor with Annular Tubules

An ovarian sex cord-stromal tumor characterized by the presence of Sertoli cells forming annular tubules. It may be associated with Peutz-Jeghers syndrome. Cases associated with Peutz-Jeghers syndrome have followed a benign clinical course. Cases which are not associated with Peutz-Jeghers syndrome have been reported having a clinically malignant course.


Stage III Ovarian Germ Cell Tumor AJCC v6 and v7

Stage III includes: T3, N0, M0. T3: Tumor involves one or both both ovaries with microscopically confirmed peritoneal metastasis outside pelvis. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage III Ovarian Cancer AJCC v8

Stage III includes: IIIA1: T1/2, N1, M0; IIIA2: T3a, N0/N1, M0; IIIB: T3b, N0/N1, M0; IIIC: T3c, N0/N1, M0. T1: Ovarian cancer with tumor limited to ovaries (one or both). T2: Ovarian cancer with tumor involving one or both ovaries with pelvic extension below pelvic brim. T3a: Ovarian cancer with microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. T3b: Ovarian cancer with macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension with or without metastasis to the retroperitoneal lymph nodes. T3c: Ovarian cancer with macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension with or without metastasis to the retroperitoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ). N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)


Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7

Stage II includes: T2, N0, M0. T2: Tumor involves one or both ovaries with pelvic extension and/or implants. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Ovarian Retiform Sertoli-Leydig Cell Tumor

A Sertoli-Leydig cell tumor of the ovary in which anastomosing, slit-like spaces resembling rete testis constitute at least 90% of the tumor elements. It may present with estrogenic and less often androgenic manifestations. It usually follows a benign clinical course.


Borderline Ovarian Mucinous Tumor/Atypical Proliferative Ovarian Mucinous Tumor

A non-invasive neoplasm that arises from the ovary and is composed of gastrointestinal-type, mucin-containing epithelial cells.  It shows greater cellular proliferation and cytologic atypia as compared to benign ovarian mucinous tumors.


Unresectable Platinum-Resistant Ovarian Carcinoma

Platinum-resistant ovarian carcinoma that is not amenable to surgical resection.


Ovarian germ cell choriocarcinoma stage IV

Stage IV includes: Any T, Any N, M1. M1: Distant metastasis (excludes peritoneal metastasis). (AJCC 6th and 7th eds.)


Borderline Ovarian Clear Cell Tumor/Atypical Proliferative Ovarian Clear Cell Tumor

A non-invasive clear cell adenofibromatous neoplasm that arises from the ovary. It is characterized by the presence of atypia in the glandular epithelium.


Stage IIIA Choroidal and Ciliary Body Melanoma AJCC v8

Stage IIIA includes: (T2c-d, N0, M0); (T3b-c, N0, M0); (T4a, N0, M0). T2c: Tumor size category 2 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in largest diameter. T2d: Tumor size category 2 with ciliary body involvement and extraocular extension less than or equal to 5 mm in largest diameter. T3b: Tumor size category 3 with ciliary body involvement. T3c: Tumor size category 3 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in largest diameter. T4a: Tumor size category 4 without ciliary body involvement and extraocular extension. N0: No regional lymph node metastasis. M0: No distant metastasis.  (AJCC 8th ed.)


beta-amyrin synthase activity

biolink:MolecularActivity biolink:BiologicalProcessOrActivity biolink:BiologicalEntity biolink:NamedThing biolink:Entity biolink:Occurrent biolink:OntologyClass biolink:ThingWithTaxon biolink:PhysicalEssenceOrOccurrent

Catalysis of the reaction: (S)-2,3-epoxysqualene = beta-amyrin. This reaction is the cyclization and rearrangement of (S)-2,3-epoxysqualene (2,3-oxidosqualene) into beta-amyrin.


isochorismate synthase activity

Catalysis of the reaction: chorismate = isochorismate.


hydroperoxy icosatetraenoate isomerase activity

A hydroperoxy icosatetraenoate <=> a hydroxy epoxy icosatrienoate.


5-(carboxyamino)imidazole ribonucleotide mutase activity

Catalysis of the reaction: 5-carboxyamino-1-(5-phospho-D-ribosyl)imidazole = 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxylate.


UDP-arabinopyranose mutase activity

Catalysis of the reaction: UDP-beta-L-arabinofuranose = UDP-beta-L-arabinopyranose.


Catalysis of the reaction: 2-(5'-methylthio)pentylmalate <=> 3-(5'-methylthio)pentylmalate.


methylaspartate mutase activity

Catalysis of the reaction: threo-3-methyl-L-aspartate = L-glutamate.


Catalysis of the reaction: glucose-1-phosphate = glucose-6-phosphate; using D-glucose as a cofactor.


Catalysis of the reaction: N-acetyl-alpha-D-glucosamine 1-phosphate = N-acetyl-D-glucosamine 6-phosphate.


squalene-hopene cyclase activity

Catalysis of the reaction: squalene = hop-22(29)-ene.


beta-lysine 5,6-aminomutase activity

Catalysis of the reaction: (3S)-3,6-diaminohexanoate = (3S,5S)-3,5-diaminohexanoate.


lysine 2,3-aminomutase activity

Catalysis of the reaction: L-lysine = (3S)-3,6-diaminohexanoate.


rRNA pseudouridine synthase activity

Catalysis of the reaction: an rRNA uridine = an rRNA pseudouridine. Conversion of uridine in an rRNA molecule to pseudouridine by rotation of the C1'-N-1 glycosidic bond of uridine in RNA to a C1'-C5.


isomaltulose synthase activity

Catalysis of the reaction: sucrose = 6-O-alpha-D-glucopyranosyl-D-fructofuranose.


D-sedoheptulose 7-phosphate isomerase activity

Catalysis of the reaction: D-sedoheptulose-7-phosphate = D-alpha,beta-D-heptose 7-phosphate.


lanosterol synthase activity

Catalysis of the reaction: (S)-2,3-epoxysqualene = lanosterol. This is a cyclization reaction that forms the sterol nucleus.


Catalysis of the reaction: 2-(3-methylthiopropyl)malate(2-) <=> 3-(3'-methylthio)propylmalate.


arabidiol synthase activity

Catalysis of the reaction: oxidosqualene + H2O = arabidiol ((13R,14R,17E)-malabarica-17,21-diene-3beta,14-diol).


chorismate mutase activity

Catalysis of the reaction: chorismate = prephenate.


3-(hydroxyamino)phenol mutase activity

Catalysis of the reaction: 3-hydroxyaminophenol = aminohydroquinone.


cycloartenol synthase activity

Catalysis of the reaction: (S)-2,3-epoxysqualene = cycloartenol.


thalianol synthase activity

Catalysis of the cyclization of 3(S)-oxidosqualene to (3S,13S,14R)-malabarica-8,17,21-trien-3-ol (thalianol).


pivalyl-CoA mutase activity

Catalysis of the reaction: pivalyl-CoA = 3-methylbutyryl-CoA.


cucurbitadienol synthase activity

Catalysis of the reaction: oxidosqualene = cucurbitadienol.


(hydroxyamino)benzene mutase activity

Catalysis of the reaction: (hydroxyamino)benzene = 2-aminophenol.


o-hydroxylaminobenzoate mutase activity

Catalysis of the reaction: o-hydroxylaminobenzoate = 3-hydroxyanthranilate.


tyrosine 2,3-aminomutase activity

Catalysis of the reaction: L-tyrosine = 3-amino-3-(4-hydroxyphenyl)propanoate.


snRNA pseudouridine synthase activity

Catalysis of the reaction: an snRNA uridine = an snRNA pseudouridine. Conversion of uridine in an snRNA molecule to pseudouridine by rotation of the C1'-N-1 glycosidic bond of uridine in RNA to a C1'-C5.


leucine 2,3-aminomutase activity

Catalysis of the reaction: L-leucine = (3R)-beta-leucine.


oxidosqualene cyclase activity

Catalysis of the cyclization of (S)-2,3-epoxysqualene to form a triterpene.


phosphopentomutase activity

Catalysis of the reaction: D-ribose 1-phosphate = D-ribose 5-phosphate.


baruol synthase activity

Catalysis of the reaction: (S)-2,3-epoxysqualene = baruol. Baruol is also known as D:B-Friedo-Baccharan-5,21-dien-3-ol.


intramolecular transferase activity, transferring acyl groups

Catalysis of the transfer of an acyl group from one position to another within a single molecule.


beta-galactosidase activity (lactose isomerization)

Catalysis of the reaction: alpha-lactose = beta-(1->6)-galactobiose.


Catalysis of the reaction: maltose = trehalose.


2-methyleneglutarate mutase activity

Catalysis of the reaction: 2-methyleneglutarate = 2-methylene-3-methylsuccinate.


2,3-bisphosphoglycerate-independent phosphoglycerate mutase activity

Catalysis of the reaction: 2-phospho-D-glycerate = 3-phospho-D glycerate; this reaction does not require the cofactor 2,3-bisphosphoglycerate.


marneral synthase activity

Catalysis of the reaction: oxidosqualene = marneral.


phosphoglucosamine mutase activity

Catalysis of the reaction: alpha-D-glucosamine 1-phosphate = D-glucosamine 6-phosphate.


Catalysis of the reaction: 2-(4'-methylthio)butylmalate <=> 3-(4'-methylthio)butylmalate.


9,12-octadecadienoate 8-hydroperoxide 8S-isomerase activity

Catalysis of the reaction: (8R,9Z,12Z)-8-hydroperoxyoctadeca-9,12-dienoate = (7S,8S,9Z,12Z)-7,8-dihydroxyoctadeca-9,12-dienoate.


Catalysis of the reaction: 4-carboxymethyl-4-methylbut-2-en-1,4-olide = 4-carboxymethyl-3-methylbut-2-en-1,4-olide.


camelliol C synthase activity

Catalyzes the reaction: (3S)-2,3-epoxy-2,3-dihydrosqualene = camelliol C.


Catalysis of the reaction: 2-(7'-methylthio)heptylmalate <=> 3-(7'-methylthio)heptylmalate.


lysolecithin acylmutase activity

Catalysis of the reaction: 1-acyl-sn-glycero-3-phosphocholine = 2-acyl-sn-glycero-3-phosphocholine.


D-ribose pyranase activity

Catalysis of the reaction: beta-D-ribopyranose = beta-D-ribofuranose.


intramolecular transferase activity, transferring amino groups

Catalysis of the transfer of an amino group from one position to another within a single molecule.


lupeol synthase activity

Catalysis of the reaction: (S)-2,3-epoxysqualene = lupeol. This reaction is the cyclization of (S)-2,3-epoxysqualene (2,3-oxidosqualene) to lupeol.


D-lysine 5,6-aminomutase activity

Catalysis of the reaction: D-lysine = 2,5-diaminohexanoate.


phosphoenolpyruvate mutase activity

Catalysis of the reaction: phosphoenolpyruvate = 3-phosphonopyruvate.


tRNA pseudouridine synthase activity

Catalysis of the reaction: tRNA uridine = tRNA pseudouridine. Conversion of uridine in a tRNA molecule to pseudouridine by rotation of the C1'-N-1 glycosidic bond of uridine in RNA to a C1'-C5.


intramolecular transferase activity, transferring hydroxy groups

Catalysis of the transfer of a hydroxyl group from one position to another within a single molecule.


Catalysis of the reaction: 2-(6'-methylthio)hexylmalate <=> 3-(6'-methylthio)hexylmalate.


Catalysis of the reaction: 4-[(1->4)-alpha-D-glucosyl](n-1)-D-glucose = 1-alpha-D-[(1->4)-alpha-D-glucosyl](n-1)-alpha-D-glucopyranoside.


Catalysis of the reaction: cobalt-precorrin 8 = cobyrinate.


precorrin-8X methylmutase activity

Catalysis of the reaction: precorrin-8X = hydrogenobyrinate.


alpha-amyrin synthase activity

Catalysis of the reaction: (S)-2,3-epoxysqualene = alpha-amyrin. This reaction is a cyclization and rearrangement of (S)-2,3-epoxysqualene (2,3-oxidosqualene) into alpha-amyrin.


2-acetolactate mutase activity

Catalysis of the reaction: 2-acetolactate = 3-hydroxy-3-methyl-2-oxobutanoate.


isobutyryl-CoA mutase activity

Catalysis of the reaction: isobutyryl-CoA = butanoyl-CoA.


D-ornithine 4,5-aminomutase activity

Catalysis of the reaction: D-ornithine = (2R,4S)-2,4-diaminopentanoate.


Catalysis of the reaction: (S)-4-amino-5-oxopentanoate = 5-aminolevulinate.


methylmalonyl-CoA mutase activity

Catalysis of the reaction: (R)-methylmalonyl-CoA = succinyl-CoA.


beta-phosphoglucomutase activity

Catalysis of the reaction: beta-D-glucose 1-phosphate = beta-D-glucose 6-phosphate.


UDP-galactopyranose mutase activity

Catalysis of the reaction: UDP-D-galactopyranose = UDP-D-galacto-1,4-furanose.


mosaic trisomy 16

Mosaic trisomy 16 is a rare chromosomal anomaly syndrome with a highly variable phenotype ranging from minor anomalies with normal development to intrauterine growth retardation, abnormal skin pigmentation, craniofacial and body asymmetry, cardiac (e.g. ventricular septal defect) and genital (e.g. hypospadias, cryptorchidism) anomalies, scoliosis and hearing loss to neonatal death. Additional features observed include skeletal malformations (e.g. clino/polydactyly, talipes), mild facial dysmorphism, and developmental delay.


double membrane vesicle viral factory outer membrane

biolink:CellularComponent biolink:AnatomicalEntity biolink:OrganismalEntity biolink:BiologicalEntity biolink:NamedThing biolink:Entity biolink:PhysicalEssence biolink:SubjectOfInvestigation biolink:ThingWithTaxon biolink:PhysicalEssenceOrOccurrent

The outer of the two endoplasmic reticulum-derived lipid bilayer membranes that bound a double membrane vesicle viral factory.


double membrane vesicle viral factory membrane

One of the two endoplasmic reticulum-derived lipid bilayer membranes that bound a double membrane vesicle viral factory.


double membrane vesicle viral factory inner membrane

The inner of the two endoplasmic reticulum-derived lipid bilayer membranes that bound a double membrane vesicle viral factory.


Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8

Stage IIIB includes: (T3, N1, M0); (T0-3, N2, M0); (T4a, N0, M0). T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Gastric Cardia Squamous Cell Carcinoma

A squamous cell carcinoma that arises from the gastric cardia.


Partington syndrome

A rare neurological condition that is primarily characterized by mild to moderate intellectual disability and dystonia of the hands. Other signs and symptoms may include dysarthria, behavioral abnormalities, recurrent seizures and/or an unusual gait (style of walking). Partington syndrome usually occurs in males; when it occurs in females, the signs and symptoms are often less severe. It is caused by changes (mutations) in the ARX gene and is inherited in an X-linked recessive manner. Treatment is based on the signs and symptoms present in each person.


hydroxynaphthoquinone

Any naphthoquinone in which the naphthaoquinone moiety is substituted by at least one hydroxy group.


Any member of the class of 1,4-naphthoquinones in which the naphthoquinone moiety is substituted by at least one hydroxy group.


5-aminovalerate transaminase activity

Catalysis of the reaction: 2-oxoglutarate + 5-aminopentanoate = 5-oxopentanoate + L-glutamate.


Catalysis of the reaction: 3-octaprenyl-4-hydroxy benzoate = 2-octaprenylphenol + CO2.


regulation of tolerance induction to tumor cell

biolink:BiologicalProcess biolink:BiologicalProcessOrActivity biolink:BiologicalEntity biolink:NamedThing biolink:Entity biolink:Occurrent biolink:OntologyClass biolink:ThingWithTaxon biolink:PhysicalEssenceOrOccurrent

Any process that modulates the frequency, rate, or extent of tolerance induction to tumor cell.


negative regulation of natural killer cell mediated immune response to tumor cell

Any process that stops, prevents, or reduces the frequency, rate, or extent of natural killer cell mediated immune response to a tumor cell.


negative regulation of response to tumor cell

Any process that stops, prevents, or reduces the frequency, rate, or extent of a response to tumor cell.


negative regulation of immune response to tumor cell

Any process that stops, prevents, or reduces the frequency, rate, or extent of an immune response to tumor cell.


positive regulation of T cell mediated cytotoxicity directed against tumor cell target

Any process that activates or increases the frequency, rate, or extent of T cell mediated cytotoxicity directed against a tumor cell target.


positive regulation of T cell mediated immune response to tumor cell

Any process that activates or increases the frequency, rate, or extent of a T cell mediated immune response to tumor cell.


negative regulation of T cell mediated cytotoxicity directed against tumor cell target

Any process that stops, prevents, or reduces the frequency, rate, or extent of T cell mediated cytotoxicity directed against a tumor cell target.


negative regulation of natural killer cell mediated cytotoxicity directed against tumor cell target

Any process that stops, prevents, or reduces the frequency, rate, or extent of natural killer cell mediated cytotoxicity directed against tumor cell target.


negative regulation of tolerance induction to tumor cell

Any process that stops, prevents, or reduces the frequency, rate, or extent of tolerance induction to tumor cell.


regulation of T cell mediated cytotoxicity directed against tumor cell target

Any process that modulates the frequency, rate, or extent of T cell mediated cytotoxicity directed against a tumor cell target.


negative regulation of T cell mediated immune response to tumor cell

Any process that stops, prevents, or reduces the frequency, rate, or extent of a T cell mediated immune response to tumor cell.


positive regulation of tolerance induction to tumor cell

Any process that activates or increases the frequency, rate, or extent of tolerance induction to tumor cell.


glucocorticoid deficiency 4

Any familial glucocorticoid deficiency in which the cause of the disease is a mutation in the NNT gene.


nasal hair

biolink:GrossAnatomicalStructure biolink:AnatomicalEntity biolink:OrganismalEntity biolink:BiologicalEntity biolink:NamedThing biolink:Entity biolink:PhysicalEssence biolink:SubjectOfInvestigation biolink:ThingWithTaxon biolink:PhysicalEssenceOrOccurrent

Hair in the nose.


morphological feature

biolink:AnatomicalEntity biolink:OrganismalEntity biolink:BiologicalEntity biolink:NamedThing biolink:Entity biolink:PhysicalEssence biolink:SubjectOfInvestigation biolink:ThingWithTaxon biolink:PhysicalEssenceOrOccurrent

A part of an organism or organ that is continuous with its surroundings and distinguished from its surroundings based on morphology.


bony projection

Anatomical projection that is composed of bone tissue.


barbed keratin-coated spine

A keratin-coated spine that is tipped with a barb.


distal limb integumentary appendage

A nail, hoof or claw.


strand of auchene hair

A truncal hair that has a single constriction and bend about midway along the hair shaft, and contains two or more air cells in the medulla.


strand of duvet hair

A strand of hair from the fine underhair of the coat.


tail hair

A strand of hair that is part of a tail.


autopod hair

A strand of hair that is part of a autopod region.


nail of manual digit 3

A nail that is part of a manual digit 3.


strand of wool

A strand of pelage hair that is crimped and grows in clusters.


nail of pedal digit 2

A nail that is part of a pedal digit 2.


primary hair

Very thin, soft, usually unpigmented, downy hair that is sometimes found on the body of a fetal or new-born human.


toilet claw

A specialized claw or nail on the foot of certain primates, used for personal grooming.


strand of pubic hair

A hair in the frontal genital area of adolescent and adult humans, located on and around the sex organs, the crotch, and sometimes at the top of the inside of the thighs, in the pubic region around the pubis bone.


nail of pedal digit 3

A nail that is part of a pedal digit 3.


keratin-coated spine

A modified strand of hair covered in a keratin coat, as found in porcupines and hedgehogs.


hair of trunk

A strand of hair that is part of a trunk.


nail of manual digit 2

A nail that is part of a manual digit 2.


strand of hair of face

A strand of hair that is part of a face.


strand of zigzag hair

A truncal hair that has two or more sharp bends with diameter constrictions at the bends, and contain one air cell in the medulla.


strand of guard hair

A long, straight truncal hair that contains two air cells in the medulla[MP]. A strand of hair from the top layer consisting of longer, often coarser, straight shafts of hair that stick out through the underfur. This is usually the visible layer for most mammals and contains most of the pigmentation.


strand of axillary hair

A strand of hair that is part of a axilla.


nail of manual digit 4

A nail that is part of a manual digit 4.


vellus hair

Short, thin, slight-colored, and barely noticeable hair that develops on most of a person's body during childhood.


pinna hair

A strand of hair that is part of a pinna.


nail of manual digit 1

A nail that is part of a manual digit 1.


strand of tylotrich hair

A single large hair, surrounded by neurovascular tissue at the level of the sebaceous gland, with a hair follicle innervated by a hair-tylotrich neuron (CL:1001436), a rapidly acting mechanoreceptor.


skeletal element projection

Anatomical projection that is composed of bone or cartilage tissue.


nail of pedal digit 5

A nail that is part of a pedal digit 5.


integumentary projection

Anatomical projection that is part of the integumentl system.


nail of manual digit 5

A nail that is part of a manual digit 5.


strand of pelage hair

A strand of hair that is part of a coat of hair.


cutaneous appendage

Anatomical projection that protrudes from the skin. Examples: hair, nail, feather, claw, hoof, horn, wattle, spur, beak, antler, bristle and some scales.


unbarbed keratin-coated spine

A keratin-coated spine that is lacks a barbed end.


pes hair

A strand of hair that is part of a pes.


manus hair

A strand of hair that is part of a manus.


hair of scalp

Hair that grows on the scalp.


nail of manual digit

A nail that is part of a manual digit.


androgenic hair

The terminal hair that develops on the human body during and after puberty. It is differentiated from the head hair and less visible vellus hair, which is much finer and lighter in color.


ventral hair

A strand of hair that is part of a ventrum.


nail of pedal digit 1

A nail that is part of a pedal digit 1.


dorsal hair

A strand of hair that is part of a dorsum.


nail of pedal digit 4

A nail that is part of a pedal digit 4.


terminal hair

Thick and long hair, as compared with vellus hair growing elsewhere.


strand of awl hair

A truncal hairs that is straight, but shorter than a guard hair, and contain two or more air cells in the medulla.


hair of head

A strand of hair that is part of a head.


Stage IV Esophageal Squamous Cell Carcinoma AJCC v7

Stage IV includes: Any T, Any N, M1, Any G, Tumor location: Any.  M1: Distant metastasis.  Tumor location: Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumor in the esophagus.  (AJCC 7th ed.)


Esophageal Well Differentiated Squamous Cell Carcinoma

An esophageal squamous cell carcinoma characterized by the presence of prominent keratinization and low mitotic activity.


Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8

Stage IV includes: IVA: (T4, N0-2, M0); (Any T, N3, M0); IVB: (Any T, Any N, M1). T4: Tumor invades adjacent structures. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)


Postneoadjuvant Therapy Stage I Esophageal Squamous Cell Carcinoma AJCC v8

Stage I includes: T0-2, N0, M0. T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Cervical Esophagus Squamous Cell Carcinoma

A squamous cell carcinoma that arises from the cervical esophagus.


Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8

Stage II includes: (T2, N0-1, M0); (T3, N0, M0). T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage II Esophageal Squamous Cell Carcinoma AJCC v7

Stage II includes: IIA (T2-3, N0, M0, G1, GX, Tumor location: Upper, middle); (T2-3, N0, M0, G2-3, Tumor location: Lower, X); IIB (T2-3, N0, M0, G2-3, Tumor location: Upper, middle); (T1-2, N1, M0, Any G, Tumor location: Any).  T2: Tumor invades muscularis propria. T3: Tumor invades adventitia. T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  N0: No regional lymph node metastasis.  N1: Metastasis in 1-2 regional lymph nodes.  M0: No distant metastasis.  G1: Well differentiated.  GX: Grade cannot be assessed-stage grouping as G1.  G2: Moderately differentiated.  G3: Poorly differentiated.  Tumor location: Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumor in the esophagus.  (AJCC 7th ed.)


Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8

Stage 0 includes: Tis, N0, M0, GN/A, Tumor location: Any. Tis: High-grade dysplasia, defined as malignant cells confined to the epithelium by the basement membrane. N0: No regional lymph node metastasis. M0: No distant metastasis. GN/A: Grade non-applicable. (AJCC 8th ed.)


Stage IB Esophageal Squamous Cell Carcinoma AJCC v7

Stage IB includes: (T1, N0, M0, G2-3, Tumor location: Any); (T2-3, N0, M0, G1, GX, Tumor location: Lower, X). T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  T2: Tumor invades muscularis propria. T3: Tumor invades adventitia. N0: No regional lymph node metastasis.  M0: No distant metastasis.  G1: Well differentiated.  GX: Grade cannot be assessed-stage grouping as G1.  G2: Moderately differentiated.  G3: Poorly differentiated.  Tumor location: Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumor in the esophagus.  (AJCC 7th ed.)


Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8

Stage IB includes: (T1a, N0, M0, G2-3, Tumor location: Any); (T1b, N0, M0, G1-3, Tumor location: Any); (T1b, N0, M0, GX, Tumor location: Any); (T2, N0, M0, G1, Tumor location: Any). T1a: Tumor invades the lamina propria or muscularis mucosae. T1b: Tumor invades the submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well-differentiated. GX: Grade cannot be assessed. G2: Moderately differentiated. G3: Poorly differentiated, undifferentiated. (AJCC 8th ed.)


Stage IIIC Esophageal Squamous Cell Carcinoma AJCC v7

Stage IIIC includes: (T4a, N1-2, M0, Any G, Tumor location: Any); (T4b, Any N, M0, Any G, Tumor location: Any); (Any T, N3, M0, Any G, Tumor location: Any).  T4a: Resectable tumor invading pleura, pericardium, or diaphragm. T4b: Unresectable tumor invading other adjacent structures, such as aorta, vertebral body, trachea, etc. N1: Metastasis in 1-2 regional lymph nodes.  N2: Metastasis in 3-6 regional lymph nodes.  N3: Metastasis in seven or more regional lymph nodes.  M0: No distant metastasis.  Tumor location: Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumor in the esophagus.  (AJCC 7th ed.)


Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8

Stage III includes: IIIA: (T0-2, N1, M0); IIIB: (T3, N1, M0); (T0-3, N2, M0); (T4a, N0, M0). T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage I Esophageal Squamous Cell Carcinoma AJCC v7

Stage I includes: IA (T1, N0, M0, G1, GX, Tumor location: Any); IB (T1, N0, M0, G2-3, Tumor location: Any); (T2-3, N0, M0, G1, GX, Tumor location: Lower, X). T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  T2: Tumor invades muscularis propria. T3: Tumor invades adventitia. N0: No regional lymph node metastasis.  M0: No distant metastasis.  G1: Well differentiated.  GX: Grade cannot be assessed-stage grouping as G1.  G2: Moderately differentiated.  G3: Poorly differentiated.  Tumor location: Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumor in the esophagus.  (AJCC 7th ed.)


Esophageal Squamous Cell Carcinoma by AJCC v7 Stage

A term that refers to the staging of esophageal squamous cell carcinoma according to the American Joint Committee on Cancer, 7th edition.


Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8

Stage IA includes: (T1a, N0, M0, G1, Tumor location: Any); (T1a, N0, M0, GX, Tumor location: Any). T1a: Tumor invades the lamina propria or muscularis mucosae. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well-differentiated. GX: Grade cannot be assessed. (AJCC 8th ed.)


Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8

Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)


Stage IIA Esophageal Squamous Cell Carcinoma AJCC v7

Stage IIA includes: (T2-3, N0, M0, G1, GX, Tumor location: Upper, middle); (T2-3, N0, M0, G2-3, Tumor location: Lower, X). T2: Tumor invades muscularis propria. T3: Tumor invades adventitia. N0: No regional lymph node metastasis.  M0: No distant metastasis.  G1: Well differentiated.  GX: Grade cannot be assessed-stage grouping as G1.  G2: Moderately differentiated.  G3: Poorly differentiated.  Tumor location: Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumor in the esophagus.  (AJCC 7th ed.)


Refractory Esophageal Squamous Cell Carcinoma

Esophageal squamous cell carcinoma that is resistant to treatment.


Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8

Stage IV includes: IVA: (T4a, N2, M0, Any G, Tumor location: Any); (T4b, N0-2, M0, Any G, Tumor location: Any); (Any T, N3, M0, Any G, Tumor location: Any); IVB: (Any T, Any N, M1, Any G, Tumor location: Any). T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)


Stage IV Esophageal Squamous Cell Carcinoma

A squamous cell carcinoma that arises from the esophagus and has metastasized to another anatomic site.


Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8

Stage IIA includes: (T2, N0, M0, G2-3, Tumor location: Any); (T2, N0, M0, GX, Tumor location: Any); (T3, N0, M0, Any G, Tumor location: Lower); (T3, N0, M0, G1, Tumor location: Upper/middle). T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. N0: No regional lymph node metastasis. M0: No distant metastasis. GX: Grade cannot be assessed. G1: Well-differentiated. G2: Moderately differentiated. G3: Poorly differentiated, undifferentiated. (AJCC 8th ed.)


Alcohol-Related Esophageal Squamous Cell Carcinoma

An esophageal carcinoma that results from alcohol consumption.  The alcohol-related esophageal carcinomas are always of squamous cell type.  There is no association between alcohol consumption and esophageal adenocarcinomas.


Esophageal Squamous Cell Carcinoma by AJCC v8 Postneoadjuvant Therapy Stage

A term that refers to the postneoadjuvant therapy staging of esophageal squamous cell carcinoma according to the American Joint Committee on Cancer, 8th edition.


Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8

Stage IVB includes: Any T, Any N, M1, Any G, Tumor location: Any. M1: Distant metastasis. (AJCC 8th ed.)


Unresectable Esophageal Squamous Cell Carcinoma

Esophageal squamous cell carcinoma that is not amenable to surgical resection.


Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v7

Stage IIIB includes: T3, N2, M0, Any G, Tumor location: Any. T3: Tumor invades adventitia. N2: Metastasis in 3-6 regional lymph nodes.  M0: No distant metastasis.  Tumor location: Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumor in the esophagus.  (AJCC 7th ed.)


Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8

Stage III includes: (T3, N1, M0); (T1-3, N2, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8


Esophageal Poorly Differentiated Squamous Cell Carcinoma

An esophageal squamous cell carcinoma characterized by the presence of basal-like malignant squamous cells that form nests, often associated with central necrosis.


Advanced Esophageal Squamous Cell Carcinoma

Esophageal squamous cell carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment


Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8

Stage 0 includes: Tis, N0, M0. Tis: High-grade dysplasia, defined as malignant cells confined to the epithelium by the basement membrane. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Stage IIB Esophageal Squamous Cell Carcinoma AJCC v7

Stage IIB includes: (T2-3, N0, M0, G2-3, Tumor location: Upper, middle); (T1-2, N1, M0, Any G, Tumor location: Any).  T2: Tumor invades muscularis propria. T3: Tumor invades adventitia. T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  N0: No regional lymph node metastasis.  N1: Metastasis in 1-2 regional lymph nodes.  M0: No distant metastasis.  G2: Moderately differentiated.  G3: Poorly differentiated.  Tumor location: Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumor in the esophagus.  (AJCC 7th ed.)


Thoracic Esophagus Squamous Cell Carcinoma

A squamous cell carcinoma that arises from the thoracic esophagus.


Esophageal Squamous Cell Carcinoma by AJCC v8 Pathologic Stage

A term that refers to the pathologic staging of esophageal squamous cell carcinoma according to the American Joint Committee on Cancer, 8th edition.


Human Papillomavirus-Related Esophageal Squamous Cell Carcinoma

An esophageal squamous cell carcinoma that arises from squamous epithelial cells infected with human papillomavirus.


Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8

Stage IVA includes: (T4a, N2, M0, Any G, Tumor location: Any); (T4b, N0-2, M0, Any G, Tumor location: Any); (Any T, N3, M0, Any G, Tumor location: Any). T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8

Stage I includes: T1, N0-1, M0. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8

Stage IIIA includes: (T1, N2, M0, Any G, Tumor location: Any); (T2, N1, M0, Any G, Tumor location: Any). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma AJCC v8

Stage II includes: T3, N0, M0. T3: Tumor invades adventitia. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Distal Esophagus Squamous Cell Carcinoma

A squamous cell carcinoma that arises from the distal esophagus.


Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal squamous cell carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Esophageal Carcinoma Cuniculatum

An extremely rare, well-differentiated squamous cell carcinoma that arises from the esophagus. It is characterized by the presence of hyperkeratosis, acanthosis, dyskeratosis, keratin-filled cysts, koilocyte-like cells, intraepithelial neutrophils, and focal cytologic atypia.


Stage IA Esophageal Squamous Cell Carcinoma AJCC v7

Stage IA includes: T1, N0, M0, G1, GX, Tumor location: Any. T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  G1: Well differentiated.  GX: Grade cannot be assessed-stage grouping as G1.  Tumor location: Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumor in the esophagus.  (AJCC 7th ed.)


Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v7

Stage IIIA includes: (T1-2, N2, M0, Any G, Tumor location: Any); (T3, N1, M0, Any G, Tumor location: Any); (T4a, N0, M0, Any G, Tumor location: Any). T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  T2: Tumor invades muscularis propria. T3: Tumor invades adventitia. T4a: Resectable tumor invading pleura, pericardium, or diaphragm. N0: No regional lymph node metastasis.  N1: Metastasis in 1-2 regional lymph nodes.  N2: Metastasis in 3-6 regional lymph nodes.  M0: No distant metastasis.  Tumor location: Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumor in the esophagus.  (AJCC 7th ed.)


Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8

Stage IIIB includes: (T2, N2, M0, Any G, Tumor location: Any); (T3, N1-2, M0, Any G, Tumor location: Any); (T4a, N0-1, M0, Any G, Tumor location: Any). T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage 0 Esophageal Squamous Cell Carcinoma AJCC v7

Stage 0 includes: Tis (HGD), N0, M0, G1, GX, Tumor location: Any.  Tis: High-grade dysplasia.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  G1: Well differentiated.  GX: Grade cannot be assessed-stage grouping as G1.  Tumor location: Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumor in the esophagus.  (AJCC 7th ed.)


Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8

Stage IVA includes: (T4a, N1-2, M0); (T4a, NX, M0); (T4b, N0-2, M0); (Any T, N3, M0). T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. NX: Regional lymph nodes cannot be assessed. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8

Stage IVA includes: (T4, N0-2, M0); (Any T, N3, M0). T4: Tumor invades adjacent structures. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8

Stage IIB includes: (T3, N0, M0, G2-3, Tumor location: Upper/middle); (T3, N0, M0, GX, Tumor location: Any); (T3, N0, M0, Any G, Tumor location: Unknown); (T1, N1, M0, Any G, Tumor location: Any). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T3: Tumor invades adventitia. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. GX: Grade cannot be assessed. G2: Moderately differentiated. G3: Poorly differentiated, undifferentiated (AJCC 8th ed.)


Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8

Stage IIIA includes: T0-2, N1, M0. T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Stage III Esophageal Squamous Cell Carcinoma AJCC v7

Stage III includes: IIIA (T1-2, N2, M0, Any G, Tumor location: Any); (T3, N1, M0, Any G, Tumor location: Any); (T4a, N0, M0, Any G, Tumor location: Any); IIIB (T3, N2, M0, Any G, Tumor location: Any); IIIC (T4a, N1-2, M0, Any G, Tumor location: Any); (T4b, Any N, M0, Any G, Tumor location: Any); (Any T, N3, M0, Any G, Tumor location: Any).  T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  T2: Tumor invades muscularis propria. T3: Tumor invades adventitia. T4a: Resectable tumor invading pleura, pericardium, or diaphragm. T4b: Unresectable tumor invading other adjacent structures, such as aorta, vertebral body, trachea, etc. N0: No regional lymph node metastasis.  N1: Metastasis in 1-2 regional lymph nodes.  N2: Metastasis in 3-6 regional lymph nodes.  N3: Metastasis in seven or more regional lymph nodes.  M0: No distant metastasis.  Tumor location: Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumor in the esophagus.  (AJCC 7th ed.)


Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8

Stage III includes: IIIA: (T1, N2, M0, Any G, Tumor location: Any); (T2, N1, M0, Any G, Tumor location: Any); IIIB: (T2, N2, M0, Any G, Tumor location: Any); (T3, N1-2, M0, Any G, Tumor location: Any); (T4a, N0-1, M0, Any G, Tumor location: Any). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)


Esophageal Squamous Cell Carcinoma by AJCC v8 Stage

A term that refers to the staging of esophageal squamous cell carcinoma according to the American Joint Committee on Cancer, 8th edition.


Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8

Stage II includes: IIA: (T2, N0, M0, G2-3, Tumor location: Any); (T2, N0, M0, GX, Tumor location: Any); (T3, N0, M0, Any G, Tumor location: Lower); (T3, N0, M0, G1, Tumor location: Upper/middle); IIB: (T3, N0, M0, G2-3, Tumor location: Upper/middle); (T3, N0, M0, GX, Tumor location: Any); (T3, N0, M0, Any G, Tumor location: Unknown); (T1, N1, M0, Any G, Tumor location: Any). T2: Tumor invades the muscularis propria. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T3: Tumor invades adventitia. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. GX: Grade cannot be assessed. G1: Well-differentiated. G2: Moderately differentiated. G3: Poorly differentiated, undifferentiated. (AJCC 8th ed.)


Esophageal Squamous Cell Carcinoma by AJCC v8 Clinical Stage

A term that refers to the clinical staging of esophageal squamous cell carcinoma according to the American Joint Committee on Cancer, 8th edition.


Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8

Stage IV includes: IVA: (T4a, N1-2, M0); (T4a, NX, M0); (T4b, N0-2, M0); (Any T, N3, M0); IVB: (Any T, Any N, M1). T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. NX: Regional lymph nodes cannot be assessed. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)


Esophageal Spindle Cell Carcinoma

An esophageal squamous cell carcinoma characterized by the presence of a spindle-cell carcinomatous component.  Crossly it has a polypoid appearance and usually arises from the middle or lower third of the esophagus.


Esophageal Moderately Differentiated Squamous Cell Carcinoma

An esophageal squamous cell carcinoma characterized by the presence of variable morphologic characteristics that include areas of prominent and poor keratinization.


Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8

Stage I includes: IA: (T1a, N0, M0, G1, Tumor location: Any); (T1a, N0, M0, GX, Tumor location: Any); IB: (T1a, N0, M0, G2-3, Tumor location: Any); (T1b, N0, M0, G1-3, Tumor location: Any); (T1b, N0, M0, GX, Tumor location: Any); (T2, N0, M0, G1, Tumor location: Any). T1a: Tumor invades the lamina propria or muscularis mucosae. T1b: Tumor invades the submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well-differentiated. GX: Grade cannot be assessed. G2: Moderately differentiated. G3: Poorly differentiated, undifferentiated. (AJCC 8th ed.)


idiopathic hypersomnia with long sleep time

Idiopathic hypersomnia with long sleep time is a sleep disorder characterized by good quality night rest of 10 hours or more, excessive daytime drowsiness that is more or less continual with long episodes of non-restorative sleep, and difficult waking with sleep drunkenness or sleep inertia.


Senior-Loken syndrome 5

Any Senior-Loken syndrome in which the cause of the disease is a mutation in the IQCB1 gene.


external ectoderm

The surface (external) layer of ectoderm which begins to proliferate shortly after separation from the neuroectoderm.


iridosome

A tissue-specific, membrane-bounded cytoplasmic organelle within which purines crystalize in reflective stacks. Iridosomes are synthesized in iridophore cells and are silver, gold or iridescent in appearance.


Stage IA Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8

Stage IA includes: T1 or T2, N0, M0, Low Mitotic Rate. T1: Tumor measuring 2 cm or less. T2: Tumor measuring more than 2 cm but not more than 5 cm. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. Low Mitotic Rate: Five or fewer mitoses per 5 square millimeters, or per 50 HPF. (AJCC 8th ed.)


Catalysis of the reaction: acetyl-CoA + phosphinothricin <=> H+ + coenzyme A(4-) + N-acetylphosphinatothricinate.


fallopian tube teratoma

A teratoma that arises from the fallopian tube. It is a rare tumor, often found incidentally.


fallopian tube germ cell tumor

A rare germ cell tumor that affects the fallopian tube. The vast majority of cases are teratomas.


fallopian tube benign neoplasm

A non-metastasizing neoplasm that arises from the fallopian tube. Representative examples include papilloma, adenofibroma, and leiomyoma.


fallopian tube leiomyoma

A benign smooth muscle neoplasm arising from the fallopian tube. It is characterized by the presence of spindle cells with cigar-shaped nuclei, interlacing fascicles, and a whorled pattern.


cancer of isthmus of fallopian tube

A cancer that involves the UBERON:0016632.


fallopian tube leiomyosarcoma

An aggressive malignant smooth muscle neoplasm, arising from the fallopian tube. It is characterized by a proliferation of neoplastic spindle cells.


fallopian tube adenosarcoma

An extremely rare malignant neoplasm that arises from the fallopian tube and is characterized by the presence of a benign epithelial component and a sarcomatous component.


fallopian tube endometrioid tumor

A benign, borderline, or malignant epithelial tumor of the fallopian tube that is characterized by the presence of glands and/or cysts lined by neoplastic cells that resemble endometrial cells.


Hurting Pain

biolink:PhenotypicFeature biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:NamedThing biolink:Entity biolink:ThingWithTaxon

A sensation of discomfort or distress that is very unpleasant.


vesicle fusion with peroxisome

The joining of the lipid bilayer membrane around a vesicle with the lipid bilayer membrane around the peroxisome.


ER-dependent peroxisome organization

A process of peroxisome organization in which assembly or arrangement of constituent parts takes place in the endoplasmic reticulum.


glyoxysome organization

A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the glyoxysome. A glyoxysome is a microbody that contains the enzymes of the glyoxylate pathway.


peroxisome inheritance

The acquisition of peroxisomes by daughter cells from the mother cell after replication. In Saccharomyces cerevisiae, the number of peroxisomes cells is fairly constant; a subset of the organelles are targeted and segregated to the bud in a highly ordered, vectorial process. Efficient segregation of peroxisomes from mother to bud is dependent on the actin cytoskeleton, and active movement of peroxisomes along actin filaments is driven by the class V myosin motor protein, Myo2p.


ER-dependent peroxisome localization

A process in which a protein is transported to, or maintained at, a location in a peroxisome via the endoplasmic reticulum.


Demodex folliculitis

A demodicidosis that involves the hair follicle.


demodicidosis

Demodicidosis is a rare parasitic cutaneous disease due to Demodex mite infestation characterized by variable degrees of spinulosis, erythema, papules, and pustules, usually accompanied by a burning or pruritic sensation. Face (incl. eyelids) is most frequently affected, but ear canal, scalp, neck, back, chest, nipples, buttocks, penis, and extremity (legs and arms) involvement have also been observed. Dermoscopic examination reveals Demodex tails and follicular openings.


demodicidosis of sebaceous gland

A demodicidosis that involves the sebaceous gland.


Mold or Dust Allergy

An allergic reaction triggered by exposure to airborne allergens expressed by dust mites or molds.


hypersensitivity reaction disease

An immune system disease that has basis in dysregulation of the hypersensitivity reaction, an inflammatory response to an exogenous environmental antigen or an endogenous antigen initiated by the adaptive immune system.


Cat allergy (disorder)

An allergic reaction triggered by exposure to allergens expressed by cats, includes allergenic factors found in feline saliva and dander.


Processed Food Allergy

An allergic reaction triggered by exposure to allergens found in processed foods.


Shellfish allergy

An allergic reaction triggered by exposure to allergens found in foods containing molluscs, crustaceans or echinoderms.


Dog Allergy

An allergic reaction triggered by exposure to allergens expressed by dogs, includes allergenic factors found in canine saliva and dander.


Venomous Ant Bite Allergy

An allergic reaction triggered by exposure to ant venom, usually as a result of being bitten by a fire ant (Solenopsis spp.).


Allergy to fruit

An allergic reaction triggered by exposure to foodborne allergens found in fruit.


type III hypersensitivity disease

Group of diseases mediated by the deposition of large soluble complexes of antigen and antibody with resultant damage to tissue. Besides serum sickness and the arthus reaction, evidence supports a pathogenic role for immune complexes in many other immune system diseases including glomerulonephritis, systemic lupus erythematosus (lupus erythematosus, systemic) and polyarteritis nodosa.


Allergy to bee venom

An allergic reaction triggered by being exposed to bee venom following a bee sting.


Contact hypersensitivity

Contact hypersensitivity is an inflammatory response induced by antigen-reactive T cells that are exposed to antigen on the skin surface (epidermis).  Poison ivy is a frequent cause of such reactivity, due to the urushiol from the plant, as are a variety of antigens derived from industrial exposure (e.g. rubber, chromate, nickel).  These antigens induce the appearance of Th1-like T cells, which presumably produce IFN to activate macrophages.


Wasp Sting Allergy

An allergic reaction triggered by being exposed to wasp venom following a wasp sting.


Dairy or Lactose Intolerance Allergy

An allergic reaction triggered by exposure to allergens found in foods containing lactose or other dairy components.


type II cellular hypersensitivity

A hypersensitivity reaction mediated by antibodies formed against cell surface antigens.


Blast Phase Myeloproliferative Neoplasm

Transformation of a myeloproliferative neoplasm into acute myeloid leukemia, typically via accelerated phase myeloproliferative neoplasm. Myeloblasts account for 20% or more of the peripheral blood white cells or the nucleated cells in the bone marrow.


Blast Phase Primary Myelofibrosis

Transformation of primary myelofibrosis into acute myeloid leukemia, typically via accelerated phase primary myelofibrosis. Myeloblasts account for 20% or more of the peripheral blood white cells or the nucleated cells in the bone marrow.


Kasabach-Merritt syndrome

Kasabach-Merritt syndrome (KMS), also known as hemangioma-thrombocytopenia syndrome, is a rare disorder characterized by profound thrombocytopenia, microangiopathic hemolytic anemia, and subsequent consumptive coagulopathy in association with vascular tumors, particularly kaposiform hemangioendothelioma or tufted angioma.


gonococcal synovitis

An synovitis (disease) caused by infection with Neisseria gonorrhoeae.


sclerema neonatorum

A diffuse hardening of skin and subcutaneous adipose tissue, associated with minimal inflammation without fat necrosis, that typically affects critically ill preterm neonates during the first week of life.


glycine formimidoyltransferase activity

Catalysis of the reaction: 5-formimidoyltetrahydrofolate + glycine = (6S)-5,6,7,8-tetrahydrofolate + N-formimidoylglycine.


Stage IB Uterine Corpus Endometrial Stromal Sarcoma AJCC v8

Stage IB includes: T1b, N0, M0. T1b: Uterine corpus endometrial stroma sarcoma with tumor limited to the uterus, measuring more than 5 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)


Fracture of Long Bone Related to Birth

An injury sustained during the birthing process in which the continuity is broken in any bone that is longer in length than width.


granulomatous disease, chronic, autosomal recessive, cytochrome b-positive, type 3


limb

A paired appendage that is evolved from a paired fin. The extent of this structure includes autopod, stylopod and zeugopod regions when present, but excludes the girdle and its parts.


right hindlimb

A hindlimb that is on the right side of a pelvic complex.


forelimb wing

Forelimb that is used to produce lift for flight through the air.


hind flipper

Hindlimb that is used to propel an animal through water.


right forelimb

A forelimb that is on the right side of a pectoral complex.


left hindlimb

A hindlimb that is on the left side of a pelvic complex.


left forelimb

A forelimb that is on the left side of a pectoral complex.


alpha-mannosidosis

Alpha-mannosidosis is an inherited lysosomal storage disorder characterized by immune deficiency, facial and skeletal abnormalities, hearing impairment, and intellectual deficit.


beta-mannosidosis

Beta-mannosidosis is a very rare lysosomal storage disease characterized by developmental delay of varying severity and hearing loss, but that can manifest a wide phenotypic heterogeneity.


anemia, nonspherocytic hemolytic, due to G6PD deficiency

An X-linked genetic condition caused by alterations in the gene G6PD that result in severely decreased activity levels of the enzyme glucose-6-phosphate dehydrogenase. Individuals with hemizygous G6PD variants associated with CNSHA have CNSHA. Individuals with G6PD variants that cause CNSHA are at risk for acute hemolytic anemia in response to certain medication exposures, chemical exposures, infections, or consumption of fava beans.


anemia, nonspherocytic hemolytic, associated with abnormality of red cell membrane